Several analysts have recently updated their ratings and price targets for Esperion Therapeutics (NASDAQ: ESPR):
- 10/5/2024 – Esperion Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 10/2/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
- 9/27/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 9/19/2024 – Esperion Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 9/11/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 9/2/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 8/22/2024 – Esperion Therapeutics was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
- 8/14/2024 – Esperion Therapeutics was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
- 8/13/2024 – Esperion Therapeutics had its price target lowered by analysts at Needham & Company LLC from $8.00 to $6.00. They now have a “buy” rating on the stock.
- 8/12/2024 – Esperion Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $16.00 price target on the stock.
Esperion Therapeutics Price Performance
Esperion Therapeutics stock opened at $2.07 on Wednesday. Esperion Therapeutics, Inc. has a 1-year low of $0.70 and a 1-year high of $3.40. The business has a fifty day moving average price of $1.83 and a 200-day moving average price of $2.19. The stock has a market capitalization of $392.18 million, a price-to-earnings ratio of -2.09 and a beta of 1.00.
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last issued its quarterly earnings results on Monday, August 12th. The biopharmaceutical company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.10. The business had revenue of $73.83 million for the quarter, compared to analysts’ expectations of $51.90 million. On average, equities research analysts anticipate that Esperion Therapeutics, Inc. will post -0.04 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
See Also
- Five stocks we like better than Esperion Therapeutics
- Quiet Period Expirations Explained
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- Roth IRA Calculator: Calculate Your Potential Returns
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Receive News & Ratings for Esperion Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.